Alimera Sciences Inc. (NASDAQ: ALIM)
$5.57
-0.0300 ( -0.54% ) 125.4K
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Market Data
Open
$5.57
Previous close
$5.60
Volume
125.4K
Market cap
$291.28M
Day range
$5.53 - $5.63
52 week range
$2.61 - $5.65
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Aug 17, 2023 |
8-k | 8K-related | 13 | Aug 15, 2023 |
3 | Insider transactions | 1 | Aug 11, 2023 |
10-q | Quarterly Reports | 82 | Aug 11, 2023 |
8-k | 8K-related | 14 | Aug 10, 2023 |
3 | Insider transactions | 1 | Aug 03, 2023 |
4 | Insider transactions | 1 | Aug 03, 2023 |
8-k | 8K-related | 19 | Aug 02, 2023 |